substance p has been researched along with levodopa in 28 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 10 (35.71) | 18.7374 |
1990's | 10 (35.71) | 18.2507 |
2000's | 6 (21.43) | 29.6817 |
2010's | 2 (7.14) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abe, H; Chihara, K; Iwasaki, J; Iwasaki, Y; Kato, Y | 1 |
Rinne, UK | 1 |
Abe, H; Chihara, K; Imur, H; Iwasaki, Y; Kato, Y; Ohgo, S | 1 |
De Ceballos, ML; Jenner, P; Marsden, CD; Rose, S; Taylor, MD | 1 |
Krause, JE; Sivam, SP | 1 |
Asanuma, M; Haba, K; Mori, A; Ogawa, N; Pongdhana, K; Sora, YH | 1 |
Chase, TN; Engber, TM; Gerfen, CR; Kuo, S; Susel, Z | 1 |
Persson, B; Rubenson, A; Sillén, U | 1 |
Rubenson, A; Sillén, U | 1 |
Gibb, JW; Hanson, GR; Sonsalla, PK | 1 |
Klawans, HL | 1 |
Abe, H; Chihara, K; Imura, H; Iwasaki, Y; Kato, Y | 1 |
Drujan, BD; Laufer, M; Negishi, K | 1 |
Rinne, UK; Tenovuo, O; Viljanen, MK | 1 |
Jenner, P; Jolkkonen, J; Marsden, CD | 1 |
Asanuma, M; Iwata, E; Kondo, Y; Matsuura, K; Nishibayashi, S; Ogawa, N | 1 |
Palmiter, RD; Zhou, QY | 1 |
Bordet, R; Carboni, S; Diaz, J; Ridray, S; Schwartz, JC; Sokoloff, P | 1 |
Drukarch, B; Stoof, JC; van de Witte, SV; Voorn, P | 1 |
Ahlenius, S; Ericson, E | 1 |
Damier, P; Féger, J; Hirsch, EC; Tremblay, L | 1 |
Andren, PE; Gunne, L; Svenningsson, P | 1 |
Arai, H; Ohrui, T; Sasaki, H; Yamaya, M; Yanai, M | 1 |
Fukuda, T; Iwata, S; Masuyama, T; Morioka, H; Nomoto, M; Shimizu, T | 1 |
Cheetham, S; Jenner, P; Lane, EL | 1 |
Andren, PE; Chergui, K; Svenningsson, P; Zhang, X | 1 |
Collier, TJ; Gebremedhin, KG; O'Malley, J; Paumier, KL; Rademacher, DJ; Sisson, KA; Sortwell, CE; Stancati, JA; Steece-Collier, K | 1 |
Ahn, S; Hong, S; Jang, J; Jeon, S; Jung, YR; Kim, J; Oh, JY; Park, HJ; Park, SU; Shin, HS; Song, MA; Song, TJ | 1 |
4 review(s) available for substance p and levodopa
Article | Year |
---|---|
Recent advances in research on Parkinsonism.
Topics: Acetylcholinesterase; Adult; Apomorphine; Benserazide; Brain; Bromocriptine; Carbidopa; Dopa Decarboxylase; Dopamine; Drug Therapy, Combination; gamma-Aminobutyric Acid; Humans; Levodopa; Norepinephrine; Parkinson Disease; Selegiline; Serotonin; Substance P; Tyrosine 3-Monooxygenase | 1978 |
Chorea.
Topics: Antipsychotic Agents; Cholinergic Fibers; Chorea; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Humans; Huntington Disease; Levodopa; Reserpine; Serotonin; Somatostatin; Substance P | 1987 |
[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Topics: Animals; Antiparkinson Agents; Biological Transport, Active; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enkephalins; Haplorhini; Humans; Levodopa; Neural Pathways; Neuronal Plasticity; Neurons, Efferent; Parkinson Disease; Receptors, Dopamine D2; Substance P; Time Factors | 2000 |
Interventions to prevent pneumonia among older adults.
Topics: Aged; Amantadine; Angiotensin-Converting Enzyme Inhibitors; Cerebrovascular Disorders; Gastroesophageal Reflux; Humans; Infection Control; Influenza Vaccines; Influenza, Human; Levodopa; Oral Hygiene; Pneumococcal Vaccines; Pneumonia; Pneumonia, Aspiration; Risk Factors; Substance P | 2001 |
24 other study(ies) available for substance p and levodopa
Article | Year |
---|---|
[Effects of biogenic amines and related neurotransmitter substances on the secretion of growth hormone].
Topics: Animals; Biogenic Amines; Growth Hormone; Hypothalamus; Levodopa; Male; Neurotransmitter Agents; Rats; Substance P | 1977 |
Growth hormone and prolactin release by substance P in rats.
Topics: Animals; Growth Hormone; Hypothalamus; Levodopa; Male; Prolactin; Rats; Secretory Rate; Substance P | 1976 |
Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia.
Topics: Animals; Carbidopa; Cholecystokinin; Chromatography, High Pressure Liquid; Corpus Striatum; Enkephalin, Leucine; Enkephalin, Methionine; Levodopa; Male; Neuropeptides; Neurotensin; Oxidopamine; Prosencephalon; Rats; Rats, Wistar; Substance P; Substantia Nigra | 1992 |
Compensatory activation of substance P biosynthesis by L-dihydroxyphenylalanine in striatonigral neurons of neonatal dopaminergic denervated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Blotting, Northern; Brain; Dopamine; Female; Injections, Intraperitoneal; Levodopa; Male; Phenylacetates; Protein Precursors; Radioimmunoassay; Rats; Rats, Inbred Strains; RNA, Messenger; Substance P; Tachykinins | 1990 |
Alterations of somatostatin and its modulation by levodopa in MPTP-treated mouse brain.
Topics: Animals; Brain Chemistry; Dopamine; Levodopa; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Norepinephrine; Sincalide; Somatostatin; Substance P; Thyrotropin-Releasing Hormone | 1990 |
Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats.
Topics: Animals; Choline O-Acetyltransferase; Corpus Striatum; Drug Administration Schedule; Dynorphins; Enkephalins; Functional Laterality; Globus Pallidus; Glutamate Decarboxylase; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains; Substance P; Substantia Nigra | 1991 |
Central effects of baclofen on the L-dopa induced hyperactive urinary bladder of the rat.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Baclofen; Bicuculline; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Injections, Intraventricular; Levodopa; Male; Naloxone; Rats; Rats, Inbred Strains; Substance P; Urinary Bladder | 1985 |
Central and peripheral motor effects of morphine on the rat urinary bladder.
Topics: Acetylcholine; Animals; Carbidopa; Dose-Response Relationship, Drug; Electric Stimulation; Injections, Intra-Arterial; Injections, Intraventricular; Levodopa; Male; Morphine; Muscle Contraction; Muscle, Smooth; Naloxone; Pelvis; Rats; Rats, Inbred Strains; Substance P; Urinary Bladder | 1986 |
Nigrostriatal dopamine actions on the D2 receptors mediate methamphetamine effects on the striatonigral substance P system.
Topics: 5,7-Dihydroxytryptamine; alpha-Methyltyrosine; Animals; Corpus Striatum; Dopamine; Hydroxydopamines; Levodopa; Male; Methamphetamine; Methyltyrosines; Oxidopamine; Rats; Rats, Inbred Strains; Substance P; Substantia Nigra; Synaptic Transmission; Tryptophan Hydroxylase | 1986 |
Effects of drugs infused into a rat hypophysial portal vessel on prolactin and growth hormone release.
Topics: Animals; Chlorpromazine; Dopamine Antagonists; Growth Hormone; Haloperidol; Levodopa; Male; Pituitary Gland; Prolactin; Rats; Substance P | 1980 |
Pharmacological manipulation of spatial properties of S-potentials.
Topics: Acetylcholine; Animals; Carbachol; Dopamine; Fishes; In Vitro Techniques; Levodopa; Membrane Potentials; Retina; Substance P | 1981 |
Substance P immunoreactivity in the post-mortem parkinsonian brain.
Topics: Aged; Antipsychotic Agents; Brain Chemistry; Female; Humans; Levodopa; Male; Parkinson Disease; Putamen; Radioimmunoassay; Substance P; Substantia Nigra | 1984 |
L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Callithrix; Caudate Nucleus; Enkephalins; Female; Gene Expression; In Situ Hybridization; Levodopa; Male; Mazindol; Motor Activity; Nucleus Accumbens; Putamen; RNA, Messenger; Substance P | 1995 |
Cholecystokinin alterations and effects of levodopa administration in the MPTP-treated mouse brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Cholecystokinin; Dopamine; Levodopa; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neuropeptides; Radioimmunoassay; Substance P; Thyrotropin-Releasing Hormone | 1995 |
Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic.
Topics: Adrenergic Fibers; Animals; Animals, Newborn; Behavior, Animal; Dopamine; Dopamine beta-Hydroxylase; Drinking Behavior; Dynorphins; Embryo, Mammalian; Feeding Behavior; Immunohistochemistry; In Situ Hybridization; Levodopa; Mesencephalon; Mice; Mice, Transgenic; Mutation; Neostriatum; Neurons; Norepinephrine; Substance P; Transgenes; Tyrosine 3-Monooxygenase | 1995 |
Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa.
Topics: Animals; Autoradiography; Behavior, Animal; Dynorphins; Gene Expression Regulation; In Situ Hybridization; Levodopa; Male; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Substance P | 1997 |
Priming with L-DOPA differently affects dynorphin and substance P mRNA levels in the striatum of 6-hydroxydopamine-lesioned rats after challenge with dopamine D1-receptor agonist.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Brain; Corpus Striatum; Dynorphins; Injections, Intraperitoneal; Injections, Subcutaneous; Levodopa; Male; Oxidopamine; Rats; Rats, Wistar; Receptors, Dopamine D1; RNA, Messenger; Stereotaxic Techniques; Substance P | 1998 |
Suggestive evidence for inhibitory effects of galanin on mesolimbic dopaminergic neurotransmission.
Topics: 5-Hydroxytryptophan; Animals; Behavior, Animal; Bradykinin; Brain Chemistry; Dopamine; Dose-Response Relationship, Drug; Galanin; Hippocampus; Injections, Intraventricular; Levodopa; Locomotion; Male; Motor Activity; Neocortex; Neostriatum; Neural Inhibition; Nucleus Accumbens; Olfactory Bulb; Peptide Fragments; Rats; Rats, Wistar; Substance P; Synaptic Transmission; Ventral Tegmental Area | 1999 |
L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset.
Topics: Animals; Benzazepines; Blotting, Western; Callithrix; Cerebral Cortex; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Antagonists; Enkephalins; Gene Expression; Genes, Immediate-Early; Levodopa; Nerve Degeneration; Oxidopamine; Parkinson Disease; Protein Precursors; Proto-Oncogene Proteins c-fos; Raclopride; Radioligand Assay; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger; Substance P; Substantia Nigra; Sympatholytics; Tritium | 2000 |
Antinociceptive mechanism of L-DOPA.
Topics: Animals; Behavior, Animal; Benserazide; Benzazepines; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Injections, Spinal; Levodopa; Male; Mice; Pain; Pain Measurement; Spinal Cord; Substance P; Time Factors | 2004 |
Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Chlorobenzenes; Corpus Striatum; Cyclobutanes; Dynorphins; Enkephalins; Gene Expression; In Situ Hybridization; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Messenger; Substance P; Time | 2008 |
Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cocaine; Disease Models, Animal; Dopamine; Feedback; Functional Laterality; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinson Disease; Peptide Fragments; Quinolines; Radioisotopes; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-3; Serine; Substance P; Sympatholytics; Tyrosine 3-Monooxygenase | 2008 |
Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration.
Topics: Aging; Amphetamine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Embryo, Mammalian; Functional Laterality; Levodopa; Neurites; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Inbred F344; Recovery of Function; Stem Cell Transplantation; Substance P | 2015 |
Effects of a combination treatment of KD5040 and
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Enkephalins; Extracellular Signal-Regulated MAP Kinases; Levodopa; Magnoliopsida; Male; Mice, Inbred C57BL; Movement; Parkinson Disease; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos; Substance P | 2017 |